Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in melanoma ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Clinical Trial Supply Agreement Announced with Regeneron for Libtayo (cemiplimab): In February, Immuneering announced a clinical trial supply agreement with Regeneron Pharmaceuticals for its anti ...

Key topics include results from the Phase 3 trial of Libtayo for high-risk cutaneous squamous cell carcinoma and data on linvoseltamab for relapsed or refractory multiple myeloma. Other research ...

Based in Tarrytown, New York, the company’s products include EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara. More Top Stocks Daily: Go behind Wall Street’s hottest headlines with ...